Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew E Aplin

Showing results (21-30 of 157) with videos related to

Pageof 16
Sort By:
Trends in Cancer|June 18, 2023
Site matters in metastatic melanomaHaley P Wilson, Andrew E Aplin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Of Mice and Melanoma: PDX System for Modeling Personalized MedicineEdward J Hartsough, Andrew E Aplin
The Journal of Investigative Dermatology|September 12, 2015
The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor ParadoxMichael J Vido, Andrew E Aplin
Trends in Cancer|August 5, 2023
Targeting TEAD-ious resistanceConnor A Ott, Andrew E Aplin
Frontiers in Bioscience (Scholar Edition)|May 31, 2011
Finding the root of the problem: the quest to identify melanoma stem cellsEthan V Abel, Andrew E Aplin
Pigment Cell & Melanoma Research|March 14, 2012
The Yin-Yang of RAF inhibitorsHa Linh Vu, Andrew E Aplin
The Journal of Investigative Dermatology|July 17, 2013
A STATement on vemurafenib-resistant melanomaEdward J Hartsough, Andrew E Aplin
Molecular Cancer Research : MCR|June 26, 2014
Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanomaHa Linh Vu, Andrew E Aplin
Cancer Research|February 27, 2009
Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensionsR Matthew Klein, Andrew E Aplin
Cancer Research|March 25, 2010
FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cellsEthan V Abel, Andrew E Aplin
Pageof 16

Showing results (21-30 of 157) with videos related to

Sort By:
Pageof 16
Trends in Cancer|June 18, 2023
Site matters in metastatic melanomaHaley P Wilson, Andrew E Aplin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Of Mice and Melanoma: PDX System for Modeling Personalized MedicineEdward J Hartsough, Andrew E Aplin
The Journal of Investigative Dermatology|September 12, 2015
The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor ParadoxMichael J Vido, Andrew E Aplin
Trends in Cancer|August 5, 2023
Targeting TEAD-ious resistanceConnor A Ott, Andrew E Aplin
Frontiers in Bioscience (Scholar Edition)|May 31, 2011
Finding the root of the problem: the quest to identify melanoma stem cellsEthan V Abel, Andrew E Aplin
Pigment Cell & Melanoma Research|March 14, 2012
The Yin-Yang of RAF inhibitorsHa Linh Vu, Andrew E Aplin
The Journal of Investigative Dermatology|July 17, 2013
A STATement on vemurafenib-resistant melanomaEdward J Hartsough, Andrew E Aplin
Molecular Cancer Research : MCR|June 26, 2014
Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanomaHa Linh Vu, Andrew E Aplin
Cancer Research|February 27, 2009
Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensionsR Matthew Klein, Andrew E Aplin
Cancer Research|March 25, 2010
FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cellsEthan V Abel, Andrew E Aplin
Pageof 16